ALS Ice Bucket Challenge Progress

 

North Carolina Clinical Trials

Duke ALS Clinic

REFALS
This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale. In this randomized, double-blind, placebo-controlled, parallel-group, multicenter study, subjects are allocated in a 2:1 ratio to receive either levosimendan (1 -2 mg daily) or placebo for 48 weeks.

GTAC (Genomic Translation for ALS Care)
The purpose of this study is to understand why ALS presents and progresses differently in patients by understanding how different genes contribute to various forms of ALS. This will in turn help researchers design more focused clinical trials for the development of treatments. Study will involve blood draws. Participant cannot be on invasive ventilation (trach & vent) or on non-invasive for more than 22 hours per day, or pregnant.

For more information, please contact:
Lisa Harrison
Clinical Research Nurse Coordinator

Wake Forest Baptist Health ALS Center

REFALS
This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale. In this randomized, double-blind, placebo-controlled, parallel-group, multicenter study, subjects are allocated in a 2:1 ratio to receive either levosimendan (1 -2 mg daily) or placebo for 48 weeks.

Centaur Study
A multicenter, randomized, double-blind, placebo-controlled 28-week study which will evaluate the safety, tolerability, efficacy, pharmacokinetics and biological activity of AMX0035 in subjects with ALS. The end goal is to slow the decline in function, muscle strength and vital capacity.
ClinicalTrials.gov Identifier: NCT03127514

CReAte Study
This is available to all pALS and PLS patients and we are collecting DNA, blood, spinal fluid (optional), and matched to exam findings to learn more about ALS. Participants will receive free genetic testing and will have the opportunity to receive their results if they like.

For more information, please contact:
Dr. Mozhdeh Marandi, MD, CCRC
ALS Research Program Manager
336-713-8577

Atrium Health Neuromuscular/ALS-MDA Center

REFALS
This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale. In this randomized, double-blind, placebo-controlled, parallel-group, multicenter study, subjects are allocated in a 2:1 ratio to receive either levosimendan (1 -2 mg daily) or placebo for 48 weeks.

For more information, please contact:
Allison Newell-Sturdivant, BSN, RN, CCRC
704-355-5285